Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52.9M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
42.7M
-
Shares change
-
-3.75M
-
Total reported value, excl. options
-
$72.6M
-
Value change
-
-$11.9M
-
Put/Call ratio
-
0.32
-
Number of buys
-
47
-
Number of sells
-
-39
-
Price
-
$1.70
Significant Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q1 2024
114 filings reported holding PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share as of Q1 2024.
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.7M shares
of 52.9M outstanding shares and own 80.7% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.48M shares), ArrowMark Colorado Holdings LLC (3.2M shares), BlackRock Inc. (3.11M shares), Euclidean Capital LLC (2.63M shares), VANGUARD GROUP INC (2.45M shares), ALKEON CAPITAL MANAGEMENT LLC (2.35M shares), ACADIAN ASSET MANAGEMENT LLC (2.08M shares), CITADEL ADVISORS LLC (1.58M shares), BANK OF AMERICA CORP /DE/ (1.37M shares), and BML Capital Management, LLC (1.31M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.